Rather than relying on signals that scale with disease burden, we profile the host response in human blood plasma as an early indicator of disease development.

By determining an individual’s proteotype, we aim to predict treatment response before therapy is prescribed.

By tracking an individual’s proteotype, we aim to monitor response during treatment, such as the emergence of resistance. We are interested in the potential to inform dosing and improve efficacy